CClinicalTrials.gg
TerminatedNCT04883008Updated Dec 20, 2023

NAVIGATE GRX Study

An observational study in Coronary Artery Disease, sponsored by Corindus Inc.. Terminated at 1 site in Poland. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-12-20.

Sponsored by Corindus Inc. · Observational

Why this study was terminated
Sponsor business decision and low enrollment
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
20 Years and older
Sex
All
01

Study summary

The objective of the present study is to detail the results of robotic-assisted PCI using technIQ automated movements in real-world clinical practice.

Read the detailed description

This multi-center, international, randomized, open-label, post-market study will enroll subjects to detail the results of robotic-assisted PCI using technIQ automated movements in real-world clinical practice by randomized comparison with a cohort of subjects undergoing robotic-assisted PCI with technIQ automated movements disabled. A secondary objective is to describe the learning curve associated with using technIQ.

02

Conditions studied

  • Coronary Artery Disease
03

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The targeted population is subjects with coronary artery disease and with a clinical indication for PCI.

Inclusion criteria

  • Male or nonpregnant female aged ≥ 20 years.
  • Patients with coronary artery disease with clinical indication for Percutaneous Coronary Intervention (PCI).
  • The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Failure/inability/unwillingness to provide informed consent.
  • In the opinion of the investigator, the subject is deemed unsuitable for robotic PCI due to clinical status or anatomic characteristics.
  • Acute STEMI within 72 hours pre-procedure.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (actual)
Patient registry
No

Groups and cohorts

  • Intervention

    CorPath GRX with technIQ automated movements enabled (technIQ ON)

    Device: CorPath GRX with technIQ automated movements enabled (technIQ ON)

  • Control

    CorPath GRX with technIQ automated movements disabled (technIQ OFF).

    Device: CorPath GRX with technIQ automated movements disabled (technIQ OFF).

Interventions

  • DeviceCorPath GRX with technIQ automated movements enabled (technIQ ON)

    The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures. TechnIQ automated movements are software-based automation of common maneuvers that interventionalists perform when manipulating catheters, guidewires, and devices by hand. In this group, automated movements will be enabled and used at the discretion of the interventionalist.

  • DeviceCorPath GRX with technIQ automated movements disabled (technIQ OFF).

    The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures. TechnIQ automated movements are software-based automation of common maneuvers that interventionalists perform when manipulating catheters, guidewires, and devices by hand. In this group, automated movements will be disabled.

05

What researchers measure

Primary outcomes

  1. Major Clinical and Angiographic Complications (MCAC)

    The rate of the combined MCAC endpoint (a composite of MACE and Major Clinical and Angiographic Complications) in the technIQ ON group is not significantly higher than in the technIQ OFF group.

    Time frame: 72 hours post-procedure or until immediately prior to discharge from the index procedure hospitalization, whichever occurs first.

  2. Technical Success

    Residual stenosis of \<30% in all target lesions with final TIMI (Thrombolysis In Myocardial Infarction) flow grade 3 by angiographic core lab analysis, AND absence of unplanned manual conversion.

    Time frame: During the Procedure

Secondary outcomes

  1. PCI procedure time

    Time between insertion of guide catheter and final removal of guide catheter.

    Time frame: During the Procedure

  2. Procedure success

    The rate of procedure success in the technIQ ON group is not significantly lower than that in the technIQ OFF group.

    Time frame: 72 hours post-procedure or until immediately prior to discharge from the index procedure hospitalization, whichever occurs first.

  3. Major adverse cardiovascular events (MACE),

    Reported as a composite and components of Cardiac Death, Target Vessel MI, and Target Vessel Revascularization (TVR).

    Time frame: 72 hours post-procedure or until immediately prior to discharge from the index procedure hospitalization, whichever occurs first.

  4. Major angiographic complications

    Reported as perforation(Type 1, 2, 3) or flow-limiting dissection (Type E, F).

    Time frame: During the Procedure

  5. Serious Adverse Events (SAE)

    All Serious Adverse Events (SAEs) from the start of the CorPath GRX PCI procedure through 72 hours postprocedure or hospital discharge (whichever occurs) first will be summarized

    Time frame: Procedure through 72 hours postprocedure or hospital discharge (whichever occurs)

  6. Guidewire Wiring Time

    The time required to advance the guidewire from the tip of the guide catheter to the final target distal to the lesion.

    Time frame: During the Procedure

  7. Fluoroscopy Time to Cross Lesion

    The fluoroscopy time required to advance the guidewire from the tip of the guide catheter to the final target distal to the lesion.

    Time frame: During the Procedure

  8. Contrast Used to Cross Lesion

    The amount of contrast (in ml) required to advance the guidewire from the tip of the guide catheter to the final target distal to the lesion.

    Time frame: During the Procedure

  9. Total Procedural Time

    The time from the start of the sheath insertion to complete removal of the final guide catheter.

    Time frame: During the Procedure

  10. Total Fluoroscopy Time

    The total fluoroscopy time during the procedure as recorded by an Imaging System.

    Time frame: During the Procedure

  11. Subject Radiation Exposure

    Dose-area-product (DAP) as recorded during the procedure

    Time frame: During the Procedure

  12. Subject Radiation Dose

    air kerma (AK) as recorded during the procedure.

    Time frame: During the Procedure

  13. Contrast Fluid Volume

    The total contrast volume used during the procedure.

    Time frame: During the Procedure

  14. Planned Manual Conversion (PMC)

    Planned manual conversion (PMC) is disengagement of the robotic drive to use bedside manipulation of either the guide catheter, guidewire, or delivery system that was prespecified in the procedural plan (e.g., to accommodate adjunctive devices or procedural techniques that are not compatible with the robotic platform, such as intravascular ultrasound or atherectomy devices). This will be assessed by a questionnaire.

    Time frame: During the Procedure

  15. Unplanned Manual Conversion (UMC)

    Unplanned manual conversion (UMC) is disengagement of the robotic drive to use bedside manipulation of either the guide catheter, guidewire, or delivery system that was not prespecified in the procedural plan, and that was due to inability to navigate to the target lesion as intended, cross the target lesion as intended, treat the target lesion as intended, retract the CorPath GRX system as intended, or other CorPath system device malfunction; or any clinical condition that requires rapid medical intervention. This will be assessed by a questionnaire.

    Time frame: During the Procedure

  16. Partial Manual Assistance (PMA)

    Partial manual assistance (PMA) is the use of manual techniques that were not prespecified in the procedural plan and do not meet the definition of unplanned manual conversion (e.g., unplanned use of manual techniques to accommodate adjunctive devices or procedural techniques that are not compatible with the robotic platform). These will be assessed by a questionnaire.

    Time frame: During the Procedure

  17. Device Malfunction

    The device malfunction will report the inadequacy of the medical device with respect to its identity, quality, durability, reliability, usability, safety, or performance. Investigators are instructed to report all device deficiencies and device malfunctions using the device malfunction form in the EDC.

    Time frame: During the Procedure

06

Study locations

1 site
  • Intercard Sp. Z o.o.
    Nowy Sącz, Poland
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04883008
Lead sponsor
Corindus Inc.
Responsible party
Sponsor
First posted
May 12, 2021
Start date
Jun 14, 2021
Primary completion
Feb 4, 2022
Completion
Feb 7, 2022
Last update
Dec 20, 2023

Study contacts

Jean Fajadet, MD
principal investigator · Groupe Cardiovasculaire Interventionnel, Clinique Pasteur

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion